Jorpes, J.E.: Heparin in the Treatment of Thrombosis, Ed. 2. Oxford University Press, London, 1946.
2.
Wright, I.S.: The pathogenesis and treatment of thrombosis with a clinical and laboratory guide to anticoagulant therapy. In Modern Medical Monographs . Grune & Stratton, Inc., New York, 1952.
3.
Koller, T., AND Merz, W. R. (Editors): Thrombosis and Embolism: Proceedings of the First International Conference. Benno Schwabe & Co., Basel, 1954.
4.
Alexander, B. , AND Wessler, S.: A guide to anticoagulant therapy. Circulation, 24: 123, 1961.
5.
Pickering, G. W. (Editor): Symposium on Anticoagulant Therapy. Harvey & Blythe, Ltd., London, 1961.
6.
Alexander, B. : Anticoagulant therapy with coumarin congeners. Action and guide lines. Am. J. Med., 33: 679, 1962.
7.
Jorpes, J.E. : Heparin, its chemistry, pharmacology and clinical use. Am. J. Med., 33: 692, 1962.
8.
Engelberg, H. : Heparin. Charles C Thomas , Springfield, III., 1962.
Bauer, G., Kallner, S., Jorpes, J.E., AND Boström, H.: Intramuscular administration of heparin. Acta med. scandinav. , 136: 188, 1950.
15.
Bauer, G.: Nine years' experience with heparin in acute venous thrombosis. Angiology, 1: 161, 1950.
16.
Warren, R., AND Belko, S.: A comparison of heparin and bishydroxycoumarin (Dicumarol) as anticoagulants . Arch. Surg., 74: 50, 1957.
17.
Carey, L.C. , AND Williams, R.D.: Comparative effects of dicoumarol, Tromexan and heparin on thrombus propagation. Ann. Surg., 152: 919, 1960.
18.
Williams, R.D. , AND Carey, L.C.: Studies in production of "Standard" venous thrombosis. Ann. Surg., 149: 381, 1959.
19.
Bauer, G.: Thirteen years' experience of heparin therapy. In Thrombosis and Embolism: First International Conference, p. 721. Benno Schwabe & Co., Basel, 1954.
20.
Engelberg, H. : Heparin in acute myocardial infarction. California Med., 91: 327, 1959.
21.
Griffith, G., Zinn, W.J., Engelberg H., Dooley, J.V., AND Anderson, R.Heparin vs. heparin bishydroxycoumarin therapy. J. A. M. A. , 174: 1157, 1960.
22.
Dimond D.G., AND Trotta P.F.: The advantages and disadvantages of using heparin as the sole anticoagulant during the first 30 days after acute myocardial infarctionDis. Chest, 40: 214, 1961.
23.
Carleton, R.A. , AND Burack W.R.: Heparin administration after acute myocardial infarction. New England J. Med., 263: 1002, 1960 .
24.
Schumacher, E.E., JR., Drake, J.R., AND Feenstra , L.H.: Heparin and the oral anticoagulants. A comparison with special reference to acute myocardial infarction . Am. J. Cardiol.9: 568, 1962.
25.
Hilden, T., Iversen, R., Raaschou, F., AND Schwartz, M.: Anticoagulants in acute myocardial infarction. Lancet, 2: 327, 1961.
26.
Friedberg, C.H.: Anticoagulants in acute myocardial infarction . J. A. M. A., 183: 904, 1963.
27.
Weiner, M., Brodie, B.B., AND Burns, J.J.: A comparative study of hypoprothrombinemic agents: the physiologic disposition and chemical pharmacology of coumarin and indanedione compounds. In Thrombosis and Embolism: Proceedings of the First International Conference, p. 181. Benno Schwabe & Co., Basel, 1954.
28.
Weiner, M., Shapiro, S., Axelrod, J., Cooper, J.R., AND Brodie, B.B.: The physiological disposition of Dicumarol in man. J. Pharmacol. & Exper. Therap., 99: 409, 1950.
29.
Schulert, A.R. , AND Weiner, M.: The physiologic disposition of phenylindanedione in man. J. Pharmacol. & Exper. Therap., 110: 451, 1954.
30.
Jaques, L.B. : The physiology of the anticoagulants. Rev. hémat., 10: 379, 1955.
31.
O'Reilly, R.A. , Aggeler, P.M., Hoag, M.S., AND Leong, L.: Studies on the coumarin anticoagulant drugs. The assay of warfarin and its biological application. Thromb. Diath. Hemorrh., 8: 82, 1962.
32.
O'Reilly, R.A. , Aggeler, P.M., AND Gibbs, J.O.: Hemorrhagic state due to surreptitious ingestion of bishydroxycoumarin. New England J. Med., 267: 19, 1962.
33.
Miller, G.J. , Mersereau, M.O., Lowen-Thal, J., AND Jaques, L.B.: Distribution of phenylindanedione in blood and tissues after oral and intravenous administration. Thromb. Diath. Haemorrh., 2: 236, 1958.
34.
O'REILLY: Unpublished data.
35.
Owren, P.A. : Thrombotest: new method for controlling anticoagulant therapy. Lancet. 2: 754, 1959.
36.
Owren, P.A. : Control of anticoagulant therapy. Arch. Intern. Med., 111: 248, 1963.
37.
Graham, J.B. : Stuart clotting defect and Stuart factor. Thromb. Diath. Haemorrh., 4: (supp.) 22, 1960.
38.
Fremont, R.E.: Bleeding complications and coagulation factors in long term anticoagulant therapy. In Transactions VIIth International Congress Internal Medicine, Munich, Germany, Sept. 1962. Vol. 1, p. 181. G. B. Thieme, Stuttgart , 1963.
39.
Fremont, R.E. , Wiedeman, M., AND Lubell D.: A comparison of bishydroxycoumarin (Dicumarol) and warfarin sodium (Coumadin) in terms of coagulation factor changes and bleeding complications. Am. J. Med. Sc., 245: 265, 1963 .
40.
Sise, H.S., Lavelle, S.M., Adams D., AND Becker M.: Relations of hemorrhage and thrombosis to prothrombin during treatment with coumarin type anticoagulants. New England J. Med., 259: 266, 1958.
41.
Fremont, R.E. , Disalvo S., AND Branstein, M.: Comparison of the Owrens' Thrombotest with the quick one-stage and the prothrombin-proconvertin test, to be published.
42.
Spooner, M. , AND Myer, O. 0.: The effect of dicoumarol (3,3'-methylenebis-4-hydroxy-coumarin) on platelet adhesiveness. Am. J. Physiol., 142: 279, 1944.
43.
Weiner, M., Zeltmacher, K., Reich, C., AND Shapiro, S.: Platelet adhesiveness. Blood, 3: 1275, 1948.
44.
Wasserman, L.R., AND Stats, D.: Clinical observations on effect of 3,3'-methylenebis-4-hydroxycoumarin . Am. J. M. Sc., 206: 466, 1943.
45.
Gilbert, N.C. , AND Nalefski, L.A.: The effect of heparin and dicoumarol in increasing the coronary flow volume. J. Lab. & Clin. Med. , 34: 797, 1949.
46.
Thompson, G.R. , Mikkelson, W.M., AND Willis, P.W.: The uricosuric effect of certain oral anticoagulant drugs. J. Lab. & Clin. Med., 52: 950, 1958.
47.
Williams, E.D. , AND Doniach, I.: The anti-thyroid activity of the anticoagulant phenylindanedione. J. Endocrinol., 21: 421, 1961.
48.
Blumberg, H. , Dayton, H.B., AND Gordon, S.M.: Bronchodilator action of the anticoagulant warfarin sodium. Science, 127: 188, 1958.
49.
Fremont, R.E. , AND Jagendorf, B.: Clinical observations on use of warfarin (Coumadin) sodium, a new anticoagulant. J. A. M. A., 165: 1381, 1957.